戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sence of the reverse-transcriptase inhibitor azidothymidine.
2 apies and blocked by the antiretroviral drug azidothymidine.
3 CaP was inhibited by the antiretroviral drug azidothymidine.
4 preparation, isolation, and reactivity of 5'-azidothymidine.
5 inhibitors have been approved for human use: azidothymidine; 2'3'-dideoxycytidine; 2'3'-dideoxyinosin
6 tudy to demonstrate the on-demand release of azidothymidine 5'-triphosphate, an anti-human immunodefi
7                    Several other substrates, azidothymidine, 9-(2-phosphonylmethoxyethyl)adenine, and
8  found that pre-incubation of the cells with azidothymidine, a pro-oxidant drug, significantly improv
9 omal cell-derived factor-1 (for HIVIIIB), or azidothymidine added during the HIV pulse, as well as by
10 ely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.
11 thymidine (d4T) >> (+)3TC >> (-)3TC > PMPA > azidothymidine (AZT) >> Carbovir (CBV).
12                           We have found that Azidothymidine (AZT) alone induces apoptosis in Epstein
13 kitt's lymphoma (BL) responded to parenteral azidothymidine (AZT) and IFN-alpha.
14 his response using the replication inhibitor azidothymidine (AZT) and RNA-Seq analysis and identified
15 e first-line ART containing stavudine (d4T), azidothymidine (AZT) and TDF on death and attrition amon
16          Sensitivity of radA recG mutants to azidothymidine (AZT) can be rescued by blocking recombin
17                                              Azidothymidine (AZT) caused progressive telomere shorten
18 ilylated nucleoside scaffold derived from 3'-azidothymidine (AZT) consistently and selectively inhibi
19 bination of interferon alpha (IFN-alpha) and azidothymidine (AZT) induces apoptosis in PEL cell lines
20               The antiviral thymidine analog azidothymidine (AZT) is used to treat several virus-asso
21 between muscle performance and CD4+ count or azidothymidine (AZT) use.
22   We also found that the antiretroviral drug azidothymidine (AZT) was an equally good substrate as th
23  replication inhibitors hydroxyurea (HU) and azidothymidine (AZT) was suppressed by alleles of dnaA t
24                                           3'-Azidothymidine (AZT) was the first approved antiviral fo
25 nergic P2X7 receptor antagonist A438079, and azidothymidine (AZT) were tested in HIV-1-infected human
26 ons to anti-HIV/AIDS pharmaceuticals such as azidothymidine (AZT), anti-malarial compounds and novel
27 oside analog reverse transcriptase inhibitor azidothymidine (AZT).
28 troviral combinations that do not include 3'-azidothymidine (AZT).
29 stic interactions is with the antiviral drug azidothymidine (AZT).
30 tes tolerance to the DNA chain-terminator 3'-azidothymidine (AZT).
31 as steeper in patients receiving zidovudine (azidothymidine [AZT], -3.64 g/dL vs. no AZT, -2.08 g/dL)
32 ne (ddC), cytarabine (ara-C) and zidovudine (Azidothymidine, AZT).
33 iency virus type 1 (HIV-1) to zidovudine (3'-azidothymidine; AZT) and appear to approximate the templ
34                 Telomerase inhibitors (i.e., azidothymidine) can represent promising antitumor agents
35 lex formation, and primer terminated with 3'-azidothymidine formed dead-end complex with 25-fold elev
36 creased the cell toxicity of ganciclovir and azidothymidine in PEL cells but had no significant effec
37 M184V suppressed the excision of 3'-deoxy-3'-azidothymidine monophosphate (AZTMP) to a greater extent
38 EA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with
39 e nucleoside reverse transcriptase inhibitor azidothymidine or the protease inhibitor indinavir to th
40  The combination of 6-TG and a RT inhibitor, azidothymidine, provided partial protection.
41 RNase H activity, in addition to the loss of azidothymidine resistance.
42 trains, and reverse transcriptase-resistant, azidothymidine-resistant, ddC/ddI-resistant, nivirapine-
43 se), which can phosphorylate ganciclovir and azidothymidine, respectively.
44  in some patients receiving 2',3'-dideoxy-3'-azidothymidine therapy in combination with 2',3'-dideoxy
45 violet light or 2,2'-dithiodipyridine and in azidothymidine-treated mice.
46 and the two nucleoside analog RT inhibitors (azidothymidine triphosphate or ddCTP), whereas two non-n
47 TP approximately alpha-thio-dTTP < dUTP < 3'-azidothymidine triphosphate).
48 ivity of several mutants was resistant to 3'-azidothymidine triphosphate.
49     When the reverse transcriptase inhibitor azidothymidine was added to the DCs during exposure to H
50                                              Azidothymidine was studied as an antineoplastic in the 1
51  the phosphorylated forms of ganciclovir and azidothymidine, we found that PEL cells exposed to hypox
52 ideoxyinosine, 2',3'-dideoxycytidine, and 3'-azidothymidine, which are known inhibitors of N1 or N2,
53 the accurate assessment of HIV inhibition by azidothymidine (zidovudine), dideoxycytidine (zalcytibin
54 vents, this study defines such a mutagen, 3'-azidothymidine [zidovudine (AZT)], used widely in the tr